Vivo Bio Tech Limited has announced a significant milestone in its growth journey with the award of a pre-clinical testing contract valued at Rs.10.75 crores for a novel molecule, in collaboration with a leading Indian pharma and agro-chemical major.

Under this contract, Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies, including toxicity studies across multiple endpoints, mutagenicity evaluations to assess genetic safety, ecotoxicology studies for environmental risk assessment, and comprehensive analytical services. All studies will be executed under Section 9(3) requirements, with regulatory submissions to the Central Insecticides Board & Registration Committee (CIBRC), India’s apex body for approvals.

By undertaking this comprehensive mandate, Vivo Bio Tech Limited joins a select group of CROs in India with the infrastructure and expertise to deliver integrated pre-clinical solutions that comply with both national and international regulatory standards.

Commenting on the achievement, Chandrasekar Patnaik, Chief Business Officer, Vivo Bio Tech Limited, said, “This milestone reaffirms Vivo Bio Tech’s scientific and technical excellence and strengthens our positioning as a trusted research partner for the global life sciences industry. It represents a major step forward in our mission to deliver innovative, reliable, and sustainable research services.”

This landmark contract further highlights Vivo Bio Tech’s growing leadership across pharmaceuticals, agrochemicals, biotechnology, and environmental sciences. It reflects the company’s long-term vision of evolving from a drug discovery services provider into a strategic co-innovator with large pharma and biotech companies. By enabling safer and more effective products to reach global markets and paving the way for future collaborations in joint drug discovery and milestone-driven partnerships, Vivo Bio Tech Limited is positioning itself as a next-generation CRO.